+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
DNA Repair Drugs Market by Drug Class (Atm Inhibitors, Atr Inhibitors, Dna Methyltransferase Inhibitors), Mechanism Of Action (Monoclonal Antibodies, Peptides, Small Molecules), Indication, Route Of Administration, End User - Global Forecast 2025-2030- Product Image
DNA Repair Drugs Market by Drug Class (Atm Inhibitors, Atr Inhibitors, Dna Methyltransferase Inhibitors), Mechanism Of Action (Monoclonal Antibodies, Peptides, Small Molecules), Indication, Route Of Administration, End User - Global Forecast 2025-2030- Product Image
Sale

DNA Repair Drugs Market by Drug Class (Atm Inhibitors, Atr Inhibitors, Dna Methyltransferase Inhibitors), Mechanism Of Action (Monoclonal Antibodies, Peptides, Small Molecules), Indication, Route Of Administration, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5977983
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The DNA repair drugs market is progressing swiftly as leading pharmaceutical companies and innovative biotechs align their efforts to advance precision medicine and redefine oncology care. Executives seeking to navigate evolving therapeutic and regulatory landscapes, optimize investments, and capitalize on emerging treatment paradigms will find critical insights for strategic planning in this comprehensive analysis.

Market Snapshot: DNA Repair Drugs Market Growth and Dynamics

The DNA repair drugs market grew from USD 9.18 billion in 2024 to USD 9.87 billion in 2025. With an expected CAGR of 7.25%, it is forecast to reach USD 13.98 billion by 2030. This growth reflects robust innovation in targeted therapies, increasing clinical trial activity, and broader adoption driven by advances in genomic medicine. Leading regions are seeing intensified collaboration, investment in new drug classes, and evolving reimbursement environments that continue to drive market momentum.

Scope & Segmentation: Key Therapeutic Classes, Indications, and Global Regions

This report delivers an in-depth segmentation of the DNA repair therapeutics landscape, mapping the competitive environment and areas of opportunity across drug types, mechanisms, and geographies.

  • Drug Classes: Atm inhibitors, Atr inhibitors, DNA methyltransferase inhibitors (launched, pipeline), Hdac inhibitors, Parp inhibitors (branded, generic, pipeline)
  • Mechanism of Action: Monoclonal antibodies, peptides, small molecules (Atm, Atr, DNA methyltransferase, Hdac, and Parp inhibitors)
  • Indications: Breast cancer (Her2 positive, hormone receptor positive, triple negative), ovarian cancer, pancreatic cancer, prostate cancer
  • Route of Administration: Intravenous, oral, subcutaneous
  • End Users: Hospitals, pharmacies, specialty clinics
  • Regional Coverage: Americas (including United States and LATAM), Europe, Middle East & Africa, Asia-Pacific (including China, Japan, India, Southeast Asia)
  • Key Companies Analyzed: AstraZeneca PLC, Merck & Co., Inc., GlaxoSmithKline plc, Clovis Oncology, Inc., Pfizer Inc.

Key Takeaways for Decision-Makers

  • Collaborative innovation is reshaping the development landscape, where partnerships between large pharmaceutical companies, biotech start-ups, and diagnostic developers accelerate the transition from research to clinical application.
  • Advances in biomarker-driven patient stratification and companion diagnostics are helping organizations personalize therapy, reduce trial timelines, and differentiate product offerings in crowded oncology submarkets.
  • Adaptive clinical trial designs and digital research platforms are enabling rapid evaluation of multiple agents, supporting agile development and faster regulatory decision-making.
  • Increasing supply chain complexity, including the need for localized and diversified manufacturing, is driving organizations to reassess procurement and production strategies for continuous market access.
  • Emergent technologies, such as AI-powered drug design and high-throughput genomic screening, serve as catalysts for expanding the pipeline and optimizing early-stage candidate selection.
  • Segment-specific insights enable targeting of underserved patient populations and tailoring commercial models to local reimbursement systems, especially in high-growth markets across Asia-Pacific and LATAM.

Tariff Impact: Supply Chain and Innovation Ecosystem Adaptation

The imposition of new United States tariffs in 2025 is increasing supply chain costs across the DNA repair drugs sector. Companies are mitigating disruptions by expanding localized manufacturing and partnering with domestic suppliers. Tariff-driven cost pressure is prompting broader risk management, onshoring discussions, and strategic reassessment of global sourcing and contract manufacturing relationships to ensure supply continuity while managing operational complexity and compliance.

Methodology & Data Sources

This report utilizes a mixed-methods approach, combining primary interviews with senior stakeholders, oncology experts, and business leaders, alongside exhaustive analysis of scientific literature, regulatory filings, and market data. Proprietary databases and scenario-based modeling ensure rigor, while cross-referencing multiple sources underpins the credibility of findings.

Why This Report Matters

  • Informs commercial, regulatory, and R&D strategies with actionable segmentation and market-access insights across regions and therapeutic classes.
  • Enables risk mitigation through analysis of tariff effects and supply chain diversification in evolving geopolitical contexts.
  • Empowers leadership to prioritize high-impact investments and partnerships using competitive analysis and pipeline coverage.

Conclusion

The DNA repair drugs market is entering a phase of accelerated advancement, fueled by scientific breakthroughs, shifting regulatory realities, and evolving commercial strategies. Senior decision-makers equipped with this strategic perspective can drive growth and enhance therapeutic impact in this transformative market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of PARP inhibitor combinations to overcome resistance in BRCA-mutated cancers
5.2. Advances in CRISPR-based targeted DNA repair therapeutics for rare genetic disorders
5.3. Development of small molecule inhibitors targeting DNA damage response kinases ATM and ATR
5.4. Growth of precision oncology pipelines focusing on synthetic lethality strategies
5.5. Integration of biomarker-driven patient selection in clinical trials for DNA repair modulators
5.6. Investment trends in AI-driven screening platforms for novel DNA repair drug candidates
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. DNA Repair Drugs Market, by Drug Class
8.1. Introduction
8.2. Atm Inhibitors
8.3. Atr Inhibitors
8.4. Dna Methyltransferase Inhibitors
8.4.1. Launched
8.4.2. Pipeline
8.5. Hdac Inhibitors
8.6. Parp Inhibitors
8.6.1. Branded
8.6.2. Generic
8.6.3. Pipeline
9. DNA Repair Drugs Market, by Mechanism Of Action
9.1. Introduction
9.2. Monoclonal Antibodies
9.3. Peptides
9.4. Small Molecules
9.4.1. Atm Inhibitors
9.4.2. Atr Inhibitors
9.4.3. Dna Methyltransferase Inhibitors
9.4.4. Hdac Inhibitors
9.4.5. Parp Inhibitors
10. DNA Repair Drugs Market, by Indication
10.1. Introduction
10.2. Breast Cancer
10.2.1. Her2 Positive
10.2.2. Hormone Receptor Positive
10.2.3. Triple Negative
10.3. Ovarian Cancer
10.4. Pancreatic Cancer
10.5. Prostate Cancer
11. DNA Repair Drugs Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. DNA Repair Drugs Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Pharmacies
12.4. Specialty Clinics
13. Americas DNA Repair Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa DNA Repair Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific DNA Repair Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AstraZeneca PLC
16.3.2. Merck & Co., Inc.
16.3.3. GlaxoSmithKline plc
16.3.4. Clovis Oncology, Inc.
16.3.5. Pfizer Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DNA REPAIR DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. DNA REPAIR DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. DNA REPAIR DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. DNA REPAIR DRUGS MARKET: RESEARCHAI
FIGURE 26. DNA REPAIR DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. DNA REPAIR DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. DNA REPAIR DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. DNA REPAIR DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY LAUNCHED, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY LAUNCHED, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 129. CANADA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 130. CANADA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 131. CANADA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 132. CANADA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 133. CANADA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 134. CANADA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 135. CANADA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 136. CANADA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 137. CANADA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 138. CANADA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 139. CANADA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. CANADA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. CANADA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 142. CANADA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 143. CANADA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 144. CANADA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 145. CANADA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. CANADA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 148. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 149. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 150. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 151. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 152. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 153. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 154. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 155. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 156. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 157. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 158. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 159. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 160. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 161. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 240. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 241. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 242. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 243. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 244. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 245. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 246. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 247. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 248. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 249. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 250. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 251. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 252. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 253. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 258. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 259. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 260. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 261. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 262. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 263. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 264. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 265. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 266. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 267. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 268. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 269. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 270. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 271. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 272. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 273. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 287. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 288. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 289. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 290. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 291. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. ITALY DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 294. ITALY DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 295. ITALY DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 296. ITALY DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 297. ITALY DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 298. ITALY DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 299. ITALY DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 300. ITALY DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 301. ITALY DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 302. ITALY DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 303. ITALY DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 304. ITALY DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 305. ITALY DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 306. ITALY DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 307. ITALY DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 308. ITALY DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 309. ITALY DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. ITALY DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 312. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 313. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 314. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 315. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 316. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 317. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 318. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 319. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 320. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 321. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 322. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 323. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 324. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 325. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 326. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 327. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 328. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 329. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 330. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 331. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 332. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 333. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 334. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 335. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 336. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 337. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 338. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 339. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD M

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this DNA Repair Drugs market report include:
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Clovis Oncology, Inc.
  • Pfizer Inc.

Table Information

Report AttributeDetails
No. of Pages190
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 9.87 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.98 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned6

Related Topics

Related Reports

DNA Repair Drugs - Global Strategic Business Report - Product Image

DNA Repair Drugs - Global Strategic Business Report

  • Report
  • 217 Pages
  • Global
From
DNA Repair Drugs Market Report 2025 - Product Image

DNA Repair Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
DNA Repair Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

DNA Repair Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Chromatin and Genomic Instability in Cancer. International Review of Cell and Molecular Biology Volume 364 - Product Image

Chromatin and Genomic Instability in Cancer. International Review of Cell and Molecular Biology Volume 364

  • Book
  • Global
DNA Repair in Cancer Therapy - Product Image

DNA Repair in Cancer Therapy

  • Book
  • 330 Pages

About the DNA Repair Drug Market

The DNA Repair Drug market is a subset of the genomics industry that focuses on the development of drugs that can repair damaged DNA. These drugs are used to treat a variety of genetic diseases, including cancer, and can be used to prevent the onset of certain diseases. DNA repair drugs are typically administered through a variety of methods, including intravenous, oral, and topical applications. The DNA Repair Drug market is highly competitive, with a number of companies vying for market share. Companies in the market include AstraZeneca, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are actively researching and developing new drugs to treat genetic diseases, as well as exploring new methods of delivery. Additionally, many of these companies are investing in research and development to create more effective treatments for genetic diseases. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.